Literature DB >> 12683258

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment.

Tonmoy Sharma1, Lena Antonova.   

Abstract

This article has discussed the relationship between cognitive deficits and functional outcome in schizophrenia. This relationship was noted first by Kraepelin and Bleuler at the beginning of the twentieth century. With the introduction of conventional neuroleptics, the focus shifted toward the treatment of positive symptoms. In the past few decades, cognitive dysfunction has been recognized as a fundamental feature of schizophrenia and has been shown repeatedly to have a negative association with functional outcome [6]. Improvement in cognitive functioning became one of the most important clinical targets in the treatment of schizophrenia in the 1990s [82]. Main domains of cognition that are disrupted significantly in schizophrenia include attention, executive function, verbal and visuospatial working memory, and learning and memory. Although conventional antipsychotics are effective in treating positive symptoms, they lack the ability to improve cognitive impairment and produce poor functional outcome. Previous research has shown superior efficacy of atypical antipsychotics on cognitive impairments in schizophrenia compared with conventional antipsychotics. Because the heterogeneity of atypical antipsychotics in their pharmacologic properties, they have differential profiles of cognitive efficacy in patients with schizophrenia. Establishing the cognitive profile of each atypical antipsychotic is an important task. This knowledge can be used to address individual cognitive problems and needs. Because cognitive deficits have been shown to have associations with different aspects of clinical symptoms, limited learning in rehabilitation programs, and functional outcome in schizophrenia, targeting individual cognitive deficits would lead to greater treatment success in terms of clinical and functional outcome. Although atypical antipsychotics have some benefit on cognitive function, further efforts to improve cognitive function are required. Attempts at improving cognition in schizophrenia with specific cognitive enhancers pharmacologically and psychological therapies such as cognitive remediation might lead to better functional outcome in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12683258     DOI: 10.1016/s0193-953x(02)00084-9

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  77 in total

Review 1.  Introduction to sertindole in clinical practice.

Authors:  Joseph Peuskens
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia.

Authors:  Elena A Spieker; Robert S Astur; Jeffrey T West; Jacqueline A Griego; Laura M Rowland
Journal:  Schizophr Res       Date:  2011-12-09       Impact factor: 4.939

3.  The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia.

Authors:  Eri Nakagami; Maanse Hoe; John S Brekke
Journal:  Schizophr Bull       Date:  2010-05-12       Impact factor: 9.306

4.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

Review 6.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

7.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

8.  Nicotine restores Wt-like levels of reelin and GAD67 gene expression in brain of heterozygous reeler mice.

Authors:  Emilia Romano; Andrea Fuso; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

9.  Multivariate Relationships Between Cognition and Brain Anatomy Across the Psychosis Spectrum.

Authors:  Amanda L Rodrigue; Jennifer E McDowell; Neeraj Tandon; Matcheri S Keshavan; Carol A Tamminga; Godfrey D Pearlson; John A Sweeney; Robert D Gibbons; Brett A Clementz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-03-31

Review 10.  Neurocognitive mechanisms of conceptual processing in healthy adults and patients with schizophrenia.

Authors:  Tatiana Sitnikova; Christopher Perrone; Donald Goff; Gina R Kuperberg
Journal:  Int J Psychophysiol       Date:  2009-12-07       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.